The A-shares of JOINN Laboratories (China) Co.,Ltd. (603127) experienced abnormal trading activity, with the cumulative deviation of closing prices exceeding 20% over three consecutive trading days on July 14th, 15th, and 16th, 2026. This constitutes an abnormal trading fluctuation as defined by the relevant regulations of the Shanghai Stock Exchange.

Following a self-review, the company has stated that its current production and operational activities are proceeding normally, with no significant changes in its internal or external operating environment. The company confirms there is no material information that should have been disclosed but has not been, which could affect the abnormal price movement of its shares.

In a separate disclosure on July 15th, 2026, the company issued a preliminary forecast for its 2026 first-half performance. It anticipates net profit attributable to shareholders of the listed company to be between approximately RMB 600 million and RMB 900 million, representing a year-on-year increase of roughly 884.9% to 1,377.4%.

The forecast for net profit attributable to shareholders after deducting non-recurring gains and losses is approximately RMB 561 million to RMB 842 million, indicating a significant year-on-year surge of about 2,334.2% to 3,551.3%.

Within this forecasted profit, the estimated contribution from fair value changes of biological assets ranges from approximately RMB 703 million to RMB 777 million. Meanwhile, the net profit from laboratory services and other business operations is projected to be between a loss of RMB 142 million and a gain of RMB 64.9736 million.